Want to join the conversation?
$ESRX's 3Q15 adjusted EBITDA increased 4% year-over-year as a result of managing specialty, formulary management and an increase in the aggregate generic fill rate. Adjusted SG&A expenses increased 2% year-over-year. Adjusted EBITDA per claim was $5.51, an increase of 4% year-over-year. $ESRX deployed approx. $1.2Bil of cash to repay debt in 3Q15.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.